Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Feb 28, 2022
Date Accepted: Aug 8, 2022

The final, peer-reviewed published version of this preprint can be found here:

Feasibility of Monitoring Patients Who Have Cancer With a Smart T-shirt: Protocol for the OncoSmartShirt Study

Steen-Olsen EB, Pappot H, Green A, Langberg H, Holländer-Mieritz C

Feasibility of Monitoring Patients Who Have Cancer With a Smart T-shirt: Protocol for the OncoSmartShirt Study

JMIR Res Protoc 2022;11(10):e37626

DOI: 10.2196/37626

PMID: 36190744

PMCID: 9577710

Feasibility of monitoring cancer patients with a smart t-shirt: Protocol for the OncoSmartShirt study

  • Emma Balch Steen-Olsen; 
  • Helle Pappot; 
  • Allan Green; 
  • Henning Langberg; 
  • Cecilie Holländer-Mieritz

ABSTRACT

Background:

Studies have shown that there may be a dissimilar perception on symptoms between cancer patients and health care professionals. This may cause that some symptomatic patients notify the clinic irregular or not at all. Wearables may help identifying symptoms earlier. Especially patients with low socioeconomic status and less awareness of own health might benefit from this. A new design of a wearable is a smart t-shirt, which has sensors embedded which generate measurements flows e.g., electrocardiogram (ECG), thoracic and abdominal respiration, and temperature.

Objective:

This study evaluates the feasibility of using a smart t-shirt for home monitoring of biometric sensor data in adolescent and young adult (AYA) and elderly patients during cancer treatment.

Methods:

The OncoSmartShirt study is an explorative study investigating the feasibility of using the ChronolifeTM Smart t-shirt during cancer treatment. This smart t-shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurements flow continuously. Twenty Danish cancer patients ≥18 years in antineoplastic treatment at Department of Oncology Rigshospitalet Denmark will be recruited from all cancer wards, whether patients are in curative or palliative care. 10 cancer patients under 39 years defined as AYA and 10 cancer patients over 65 years defined as elderly. Consenting patients will be asked to wear a smart t-shirt daily for 2 weeks during their treatment course.

Results:

The primary outcome is to determine if it is feasible to wear a smart t-shirt throughout the day (preferably 8 hours pr day) for 2 weeks. Inclusion of patients will begin in March 2022.

Conclusions:

The study will assess the feasibility of using the ChronolifeTM smart t-shirt for home monitoring of vital parameters in cancer patients during their treatment and bring new insights to how wearables and biometric data can be used as part of symptom recognition in cancer patients during treatment in the quest of increasing patients’ quality of life. Clinical Trial: This trial is registered at clinicaltrials.gov (NCT05235594). The study is conformed to the guidelines of General Data Protection Regulation (GDPR) and is registered at the Capital Region of Denmark (P-2021-357).


 Citation

Please cite as:

Steen-Olsen EB, Pappot H, Green A, Langberg H, Holländer-Mieritz C

Feasibility of Monitoring Patients Who Have Cancer With a Smart T-shirt: Protocol for the OncoSmartShirt Study

JMIR Res Protoc 2022;11(10):e37626

DOI: 10.2196/37626

PMID: 36190744

PMCID: 9577710

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.